Clinical Trial Update: TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating intranasal oxytocin (TI-001) for high-frequency episodic migraine and chronic migraine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• TI-001 (intranasal oxytocin) (oxytocin)

Snippet

Sponsor: Trigemina, Inc | Conditions: High Frequency Episodic Migraine and Chronic Migraine | Phase 2 | Status: COMPLETED